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Background: There is currently no consensus regarding the optimal timing for androgen suppression therapy in
patients with prostate cancer that have undergone local therapy with curative intent but are proven to have
node-positive disease without signs of distant metastases at the time of local therapy. The objective of this
systematic review was to determine the benefits and harms of early (at the time of local therapy) versus deferred
(at the time of clinical disease progression) androgen suppression therapy for patients with node-positive prostate
cancer after local therapy.
Methods: The protocol was registered prospectively (CRD42011001221; http://www.crd.york.ac.uk/PROSPERO). We
searched the MEDLINE, EMBASE, and CENTRAL databases, as well as reference lists, the abstracts of three major
conferences, and three trial registers, to identify randomized controlled trials (search update 04/08/2012). Two
authors independently screened the identified articles, assessed trial quality, and extracted data.
Results: Four studies including 398 patients were identified for inclusion. Early androgen suppression therapy lead
to a significant decrease in overall mortality (HR 0.62, 95% CI 0.46-0.84), cancer-specific mortality (HR 0.34, 95% CI
0.18-0.64), and clinical progression at 3 or 9 years (RR 0.29, 95% CI 0.16-0.52 at 3 years and RR 0.49, 95% CI 0.36-0.67
at 9 years). One study showed an increase of adverse effects with early androgen suppression therapy. All trials had
substantial methodological limitations.
Conclusions: The data available suggest an improvement in survival and delayed disease progression but increased
adverse events for patients with node-positive prostate cancer after local therapy treated with early androgen
suppression therapy versus deferred androgen suppression therapy. However, quality of data is low. Randomized
controlled trials with blinding of outcome assessment, planned to determine the timing of androgen suppression
therapy in node-positive prostate cancer using modern diagnostic imaging modalities, biochemical testing, and
standardized follow-up schedules should be conducted to confirm these findings.
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Prostate cancer is a relevant tumor with an increased
morbidity and mortality [1,2]. The treatment options for
prostate cancer confined to the prostate gland (localized
disease) consist of radical prostatectomy or radiotherapy
[3]. In men with low and intermediate risk localized
prostate cancer (cT1a-T2b, Gleason score 2–7, PSA <
20 ng/mL) and life expectancy > 10 years [3], the goal of
local therapy is the eradication of disease (local therapy
with curative intent). The prognosis for these patients is
excellent. However, advanced-stage prostate cancer with
regional lymph node involvement or metastases is usu-
ally regarded as systematic disease with a potentially in-
creased risk for morbidity and mortality.
Since the primary work of Huggins & Hodges on
hormonal ablation therapy in prostate cancer [4], an-
drogen suppression therapy (AST) has become an im-
portant non-curative therapeutic option to slow the
progression of advanced prostate cancer [5]. The andro-
gen testosterone is essential for prostate cell growth,
and its suppression is therefore important in prostate
cancer therapy. Androgen suppression can be achieved
either by surgical castration or by luteinizing hormone
releasing hormone (LHRH) agonists. LHRH agonists
were found to be as effective as surgical castration with
bilateral orchiectomy [5]. Antiandrogens inhibit the ac-
tion of the circulating hormones at the level of andro-
gen receptors in prostate cells. This therapy option is
recommended for short-term administration in patients
receiving LHRH agonists and non-steroidal antiandrogen
monotherapy as an alternative to castration in patients
with locally advanced prostate cancer [5]. LHRH antago-
nists are a new family of AST agents. However, whether
they have advantages over LHRH agonists has not yet
been determined [5].
Patients that have undergone local treatment for sup-
posedly localized disease with curative intent but were
proven to be node-positive due to a definitive patho-
logical examination that revealed no distant metastases
are a therapeutic challenge because of the controversy
concerning when to initiate hormonal therapy [5]. For
these asymptomatic patients, therapy options that fur-
ther slow progression with potentially increased side ef-
fects must be carefully balanced with a “wait and see”
attitude and the possibility that this approach will in-
crease the rate of disease progression. Therefore, two
different types of AST administration are usually
discussed: administration at the time of local therapy
(early AST) or administration when there are signs and
symptoms of clinical disease progression (deferred AST)
[5]. To date, no systematic review has critically assessed
the benefits and harms of early versus deferred AST for
the subgroup of patients presenting with lymph node-
positive disease at the time of local therapy.Methods
The protocol was prospectively registered in the ‘Inter-
national prospective register of systematic reviews’ (www.
crd.york.ac.uk/PROSPERO;CRD42011001221). We con-
ducted a combination of electronic and manual searches.
First, we identified potentially eligible studies from the
CENTRAL (Cochrane Library 2011/Issue 2), MEDLINE
(Ovid, 1946-02/2011), and EMBASE (DIMDI, 1947-02/
2011) databases. The search strategy was adapted for each
electronic database (Table 1). Second, we screened refer-
ence lists and performed electronic searches for abstracts
on the websites of major conferences (initial search 18/05/
2011): the American Society of Clinical Oncology (ASCO,
2004-18/05/2011, http://jco.ascopubs.org), the European
Association of Urology (EAU, 2004-18/05/2011, www.
uroweb.org), and the American Urological Association
(AUA ,2002-2007, www.abstracts2view.com/aua_archive/;
2008, www.abstracts2view.com/aua; 2009-18/05/2011,
www.jurology.com). We also searched the following three
trial registers for completed or ongoing studies (initial
search 18/05/2011): Current Controlled Trials (ISRCTN,
www.controlled-trials.com), ClinicalTrials.gov (www.clini
caltrials.gov), and the clinical trials search portal of the
World Health Organization: (ICTRP, www.who.int/ictrp/
en/). We updated our search on April 8, 2012.
We considered parallel group RCTs that met the fol-
lowing criteria: patients had (1) node-positive prostate
cancer at the time of local therapy (radical prostatec-
tomy with lymphadenectomy or radiotherapy with either
mandatory imaging or histological lymph node assess-
ment), (2) received no prior AST, and (3) had no signs
of distant metastases at the time of study entry. (4) All
of the studies compared early AST (initiated at the time
of local therapy) with deferred AST (initiated at the time
of disease progression) for the treatment of advanced
prostate cancer and (5) reported data on overall survival,
cancer-specific survival, progression-free survival, dis-
continuation due to adverse events, or any adverse
events. Whether LHRH antagonists have advantages
over LHRH agonists or antiandrogens has not yet been
determined [5]. However, LHRH antagonists are not part
of this systematic review. We excluded publications
reporting on patients who developed lymph node metas-
tasis after local treatment (by radical prostatectomy or
radiotherapy). We did not impose any limitations based
on the age or ethnicity of the participants or the lan-
guage of the publication.
One author (FK) screened all of the titles and abstracts
of the citations identified by our search strategy and only
excluded citations that were clearly irrelevant or were
retrieved from more than one database (exclusion of du-
plicate entries). As a next step, two review authors (FK,
BK) independently examined the full-text reports, identi-
fied relevant studies, assessed the risk of bias (random
Table 1 Search strategies
Database Search strategy
Ovid MEDLINEW In-Process & Other Non-Indexed Citations, Ovid
MEDLINEW Daily and OVID MEDLINEW (1946-April 8, 2012)
1: Prostatic Neoplasms/; 2: (prostat* adj3 (cancer* or tumo* or neoplas* or
carcinom* or malign*)).tw.; 3: 1 or 2; 4: Lymph Nodes/pa, su; 5: Lymphatic
Metastasis/; 6: Neoplasm Invasiveness/; 7: (nod* adj3 positiv*).mp.; 8: N1.mp.; 9: D1.
mp.; 10: N2.mp.; 11: (lymph* adj3 (metastas* or tumo* or neoplas* or carcinom* or
malign*)).mp.; 12: 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11; 13: Lymph Node Excision/;
14: lymphadenectom*.mp.; 15: (lymph* adj3 (surg* or operat* or excis* or removal*)).
mp.; 16: 13 or 14 or 15; 17: randomized controlled trial.pt.; 18: controlled clinical trial.pt.;
19: placebo.ab.; 20: drug therapy.fs.; 21: randomly.ab.; 22: trial.ab.; 23: groups.ab.; 24:
randomized.ab.; 25: 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24; 26: exp animals/ not
humans.sh.; 27: 25 not 26; 28: 3 and 12 and 16 and 27
EMBASE (1947-April 8, 2012) 1: EM74; 2: CT=("PROSTATE TUMOR"; "PROSTATE CANCER"; "PROSTATE
ADENOCARCINOMA"; "PROSTATE CARCINOMA"); 3: (prostat* and (cancer* or tumo*
or neoplas* or carcinom* or malign*))/same sent; 4: 2 OR 3; 5: CT=("LYMPH NODE";
"MESENTERY LYMPH NODE"; "PARAAORTIC LYMPH NODE"; "PELVIS LYMPH NODE");
6: CT="LYMPH NODE METASTASIS"; 7: CT="CANCER INVASION"; 8: (nod* and
positiv*)/same sent; 9: N1 or N2 or D1; 10: (lymph* and (metasta* or tumo* or
neoplas* or carcinom* or malign*))/same sent; 11: 5 OR 6 OR 7 OR 8 OR 9 OR 10;
12: CT=("LYMPHADENECTOMY"; "LYMPH NODE DISSECTION"; "PELVIS
LYMPHADENECTOMY"); 13: (lymph* and (surg* or operat* or excis* or remov*))/
same sent; 14: lymphadenectom*; 15: 12 OR 13 OR 14; 16: 4 AND 11 AND 15; 17:
su=medline; 18: 16 not 17; 19: CT=("CONTROLLED CLINICAL TRIAL"; "RANDOMIZED
CONTROLLED TRIAL"); 20: CT="RANDOMIZATION"; 21: CT="DOUBLE BLIND
PROCEDURE"; 22: CT="SINGLE BLIND PROCEDURE"; 23: CT="PROSPECTIVE STUDY";
24: RANDOM*; 25: ((SINGL* OR DOUBL*) AND (BLIND* OR MASK*))/SAME SENT; 26:
(CONTROLLED AND TRIAL)/SAME SENT; 27: ti=trial; 28: groups; 29: 19 OR 20 OR 21
OR 22 OR 23 OR 24 OR 25 OR 26 OR 27 OR 28; 30: 18 AND 29
Cochrane Database of Systematic Reviews, Cochrane Central
Register of Controlled Trials (CENTRAL)
1: MeSH descriptor Prostatic Neoplasms, this term only; 2: (prostat* NEAR/3 (cancer*
OR tumo* OR neoplas* or carcinom* or malign*)); 3: (1 OR 2); 4: MeSH descriptor
Lymph Nodes, this term only; 5: MeSH descriptor Lymphatic Metastasis, this term
only; 6: MeSH descriptor Neoplasm Invasiveness, this term only; 7: (nod* NEAR/3 positiv*);
8: (N1 OR N2 OR D1); 9: (lymph NEAR/3 (metastas* OR tumo* OR neoplas* OR carcinom*
OR malign*)); 10: (4 OR 5 OR 6 OR 7 OR 8 OR 9); 11: MeSH descriptor Lymph Node
Excision, this term only; 12: (lymphadenectomy); 13: (lymph* NEAR/3 (surg* OR operat*
OR excis* OR removal*)); 14: (11 OR 12 OR 13); 15: (3 AND 10 AND 14)
Date of last search: April 8, 2012; Responsible searcher: Kunath, Motschall.
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complete outcome data, selective reporting, and other
sources of bias) and extracted data on study/patient char-
acteristics as well as data on our predefined outcomes.
Disagreements were resolved by consensus or, if necessary,
through discussion with a third review author (JM).
For statistical data analysis, we used RevMan 5.1 soft-
ware provided by The Cochrane Collaboration (www.
cochrane.org). For time-to-event outcomes, we either
extracted hazard ratios (HR) with their 95% confidence
intervals (CI) or used an indirect estimation method for
estimation [6-8] if HR were not given (see overall sur-
vival and cancer-specific survival). If this was not pos-
sible, we calculated risk ratios (RR) with their 95% CI at
certain time points (see clinical progression at 3 or 9 -
years). We assessed statistical heterogeneity (Chi2, I2)
and used a fixed-effect model for I2 < 50%. A random-
effects model was used for sensitivity analysis if I2 > 50%.
Results
Search results
The literature search identified a total of 930 citations. A
total of 9 reports on 4 studies were finally included inthe review. For details on results of the search, see
Figure 1. We identified no ongoing studies, and no fur-
ther subgroup analysis of excluded studies fulfilled our
predefined inclusion criteria. We identified no additional
study with our updated search. The following trials were
included in our analysis: (1) RTOG-85-31, which was
performed by the Radiation Therapy Oncology Group
[9,10], (2) a study published by Granfors et al. [11,12],
(3) EST-3886, a study performed by the Eastern Co-
operative Oncology Group [13-15], and (4) EPC pro-
gram, which was performed by the Early Prostate
Cancer Program [16,17]. Lymph-node assessment by
either imaging or surgical means was mandatory in
all studies. Patients were stratified to nodal status be-
fore randomization. From three studies (RTOG-85-31,
Granfors et al., EPC program), we included only the sub-
groups of patients with node-positive prostate cancer
after local therapy with curative intent. Only one study
(EST-3886) specified the total number of assessed lymph
nodes as well as the number of positive lymph nodes in
the lymphadenectomy specimen (Table 2). Table 3 re-
ports details on the study characteristics, and Table 2
provides information on patients’ baseline characteristics.
Figure 1 Search results.
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For details, see Tables 4 and 5.
Overall survival
Three studies (RTOG-85-31, Granfors et al., EST-3886),
with a combined total of 310 patients with node-positive
prostate cancer, provided data on overall survival. The
results demonstrated a statistically significant difference
favoring early AST as compared with deferred AST after
a minimum median follow-up of 6.5 years (Figure 2, HR
0.62; 95% CI 0.46-0.84). Both local treatments (radical
prostatectomy and radiotherapy) revealed significant
benefits of early AST (see Figure 2). However, using the
random-effects model for heterogeneity (I2 = 73%) for
overall survival with radiotherapy revealed no significant
difference (HR 0.56; 95% CI 0.26-1.21; not shown). The
total effect with random-effects model, however, showed
still a significant benefit favoring early AST as compared
with deferred AST (HR 0.57; 95% CI 0.37-0.90, not
shown).
Cancer-specific survival
Two studies (Granfors et al., EST-3886) reported data
on cancer-specific survival. However, we were not ableto include both studies in the meta-analysis because they
included insufficient amounts of detail. Granfors et al.
stated only that “among lymph node positive patients
there was a significantly poorer prognosis after radio-
therapy alone (and AST at clinical progression; deferred
AST) than after combined treatment (early AST)
(p = 0.01)” [12]. EST-3886 reported data for cancer-
specific survival favoring early AST as compared with
deferred AST after a median follow-up of 11.9 years
(Figure 3, HR 0.34; 95% CI 0.18-0.64).
Clinical progression
Four studies (RTOG-85-31, Granfors et al., EST-3886,
EPC program) reported data on clinical progression. For
the definitions of clinical progression used, see Table 3.
Three studies were included in a meta-analysis for clin-
ical progression at 3 years (RTOG-85-31, EST-3886,
EPC program) or 9 years of follow-up (RTOG-85-31,
Granfors et al., EST-3886). Pooled analysis demonstrated
a statistically significant benefit for early AST as com-
pared to deferred treatment for both time points
(Figure 4, RR 0.29, 95% CI 0.16-0.52 at 3 years and
Figure 5, RR 0.49, 95% CI 0.36-0.67 at 9 years, respect-
ively). The benefit of non-steroidal antiandrogens has
Table 2 Baseline patient characteristics














(n = 150) (a)
Age (years) median 64 median 66 mean 68.8 median 65.1 median 66.6 mean 64.6
(range 44–79) (range 50–77) (range 49.2-75.3) (range 52–75) (range 45–78) (range 52–84)
Gleason score (n) not known 10 10 - - 3 6 5
2-4 - - - - - - 22
5-6 - - - - - - 60
3-6 - - - - 9 11 -
2-7 55 43 - - - - -
7 - - - - 26 29 -
7-10 - - - - - - 63
8-10 33 22 - - 9 5 -
Grade (n) G1 - - 3 4 - - -
G2 - - 13 12 - - -
G3 - - 4 3 - - -
T stage (n) T1 3 6 2 2 - - 43
T2 68 53 13 11 - - 98
T3 27 16 4 6 - - 9
T4 - - 1 0 - - 0
Positive surgical margins (n) - - - - 32 31 -
Positive seminal vesicle (n) - - - - 27 32 -
Nodal status (n) assessed - - - - median 11 median 14 -
(range 3–36) (range 2–39)
positive - - - - median 2 median 2 -
(range 1–19) (range 1–20)
(a). Authors reported data for baseline patient characteristics only for the group of patients with node-positive prostate cancer but not for patients randomized to
early or deferred androgen suppression therapy.
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sensitivity analysis to test the robustness of results. The
effect of early AST on clinical progression at 3 years
remained significant after exclusion of non-steroidal
antiandrogen data (EPC program) from pooled analysis
(RR 0.27, 95% CI 0.13-0.56; not shown). Sensitivity ana-
lysis for clinical progression at 3 years for the subgroup
treated with radical prostatectomy (I2 = 57%) using the
random-effects model revealed a significant difference
favoring early AST as compared with deferred AST (HR
0.21; 95% CI 0.06-0.78; not shown). The total effect still
showed a more beneficial effect for early AST (HR 0.31;
95% CI 0.14-0.71, not shown). This was also revealed by
the sensitivity analysis for clinical progression at 9 years
for patients that had received radiotherapy (I2 = 58%).
Early AST still showed a more beneficial effect than de-
ferred AST when analyzed using a random-effects model
(HR 0.52; 95% CI 0.28-0.98, not shown). The total effect
was more favorable for early AST at 9 years (HR 0.47;
95% CI 0.30-0.73, not shown) 7.Biochemical progression
The Early Prostate Cancer Program presented data on a
composite endpoint including biochemical progression
(defined by the earliest occurrence of prostate specific
antigen (PSA) doubling from baseline), clinical disease
progression, or death in the absence of progression at 3 -
years’ median follow-up after radical prostatectomy in
patients with node-positive prostate cancer. The authors
noted a significant difference favoring early AST com-
pared with deferred therapy that was initiated at the on-
set of clinical progression (HR 0.11, 95% CI 0.04-0.30)
[16,17]. RTOG-85-31 reported data including PSA pro-
gression (defined as a PSA elevation of greater than
1.5 ng/ml or 4 ng/ml after 6 years’ median follow-up fol-
lowing radiotherapy) showing a beneficial effect of early
compared to deferred AST (PSA >1.5 ng/ml: p < 0.0001
or PSA >4 ng/ml: p < 0.0001, respectively) [9]. However,
RTOG-85-31 was initiated before the widespread use of
PSA testing. PSA measurement was introduced later in
the study. Consequently, PSA was not routinely used as
Table 3 Study characteristics
RTOG-85-31 [9,10] Granfors et al. [11,12] EST-3886 [13-15] EPC program [16,17]
Design prospective RCT (1987–1992) prospective RCT (1986–1991) prospective RCT (1988–1993) prospective RCT (1995–1998)
Included
participants
173 patients with lymph node-positive prostate cancer
and no distant metastases at study entry; no prior AST
39 patients with lymph node-
positive prostate cancer and no
distant metastases at study
entry; no prior AST
98 patients with lymph node-
positive prostate cancer and no
distant metastases at study
entry; no prior AST
88 patients with lymph node-positive prostate
cancer and no distant metastases at study entry; no
prior AST




radical prostatectomy radical prostatectomy (74 patients) or radiotherapy
(14 patients; mean 65 Gy) (c)
Lymph node
assessment










LHRH analogues (goserelin, initiated during last week of
radiotherapy; 98 patients)
orchiectomy (initiated at time of
local therapy; 20 patients)
LHRH analogues (goserelin)/
orchiectomy (initiated at time of
local therapy; 47 patients)
anti-androgen (bicalutamide 150 mg daily) (initiated
at time of local therapy, 42 patients)
Control
(deferred AST)
LHRH analogues (initiated at clinical progression; 75
patients) (a)
LHRH analogues/orchiectomy
(initiated at clinical progression;
19 patients) (a)
LHRH analogues/orchiectomy
(initiated at clinical progression;
51 patients) (a, b)
AST at investigators discretion (initiated at clinical
progression; 46 patients) (a)
Follow-up median 6.5 years for all patients, 9.5 year for survivors median 9.3 years for all patients
(14–19 years), 16.5 years for
survivors




local progression: reappearance of palpable tumor after
initial clearance, progression of palpable tumor (at any
time), or biopsy-proven presence of carcinoma of the
prostate 2 years or more after study entry. regional
progression: clinical or radiographic evidence of tumor in
the pelvis with or without palpable tumor in the prostate
by digital examination (a)
occurrence of clinical evident
local tumor growth or bone or
other distant metastases (a)
evidence of recorded clinical
progression or death from any
cause (a)
occurrence of objective progression (confirmed by
bone scan, magnetic resonance imaging,
ultrasonography, or computed tomography scan) or
death without progression (a)
AST, androgen suppression therapy; RCT, randomized controlled trial; Gy, Gray; LHRH, luteinising hormone-releasing hormone.
(a). Testing of prostate-specific antigen (PSA) was not used for definition of clinical progression.
(b). Use of AST was delayed if only local recurrence was suspected and physicians were advised to treat with local treatment (i.e. radiotherapy) first [13,15].
(c). Besides radical prostatectomy and radiotherapy, watchful waiting was also investigated as standard treatment. Only patients that underwent local therapy (radical prostatectomy, radiotherapy) were included in
this review.

















Table 4 Risk of bias






not described random number generator random number generator
allocation
concealment












low risk (a) low risk (a) low risk (a) low risk (a)
selective
reporting








staging was retrospectively regraded to ensure
comparable groups; initially planned for 400 patients
but stopped after inclusion of 91 of which only 39
patients (43%) presented with lymph node-positive
disease.
staging was retrospectively regraded to ensure
comparable groups; initially planned for 220 lymph
node-positive patients but stopped after inclusion
of 100 of which only 98 were randomized
randomization of 8113 patients but only 150
(2%) presented lymph node-positive disease
(radical prostatectomy: 74 patients, radiotherapy:
14 patients, watchful waiting: 62 patients).
(a). We found no evidence for missing outcome data for patients with node-positive prostate cancer. Additionally, survival/progression outcome data were presented by intention-to-treat.
(b). The study protocol is not available but we suggest that the published reports include all expected outcomes.
(c). One or more outcomes of interest are reported incompletely so that they cannot be entered in a meta-analysis.
(d). Authors reported data for adverse events in the subgroup of patients with node-positive prostate cancer inconsistently. However, adverse events were reported sufficiently for all patients included in the study in

















Table 5 Grading the quality of evidence




bias Inconsistency Indirectness Imprecision
Other
considerations















170 fewer per 1000 (from 64
fewer to 264 fewer)
⊕⊕ΟΟ
low











285 fewer per 1000 (from 140
fewer to 376 fewer)
⊕⊕ΟΟ
low











183 fewer per 1000 (from 124
fewer to 216 fewer)
⊕⊕ΟΟ
low











276 fewer per 1000 (from 179
fewer to 347 fewer)
⊕⊕ΟΟ
low
1 EST-3886: Random sequence generation: Random number generator; Allocation concealment: Central allocation; Blinding of participants/personnel: No (only pathologists were blinded); Blinding of outcome
assessment: Unclear; Incomplete outcome data: We found no evidence for missing outcome data for patients with node-positive prostate cancer and survival/progression outcome data were presented by intention-
to-treat; Selective reporting: The study protocol is not available but we suggest that the published reports include all expected outcomes; Note: Staging was retrospectively regraded to ensure comparable groups.
2 Granfors et al.: Random sequence generation: Not described; Allocation concealment: Not described; Blinding of participants/personnel: No; Blinding of outcome assessment: Unclear; Incomplete outcome data: We
found no evidence for missing outcome data for patients with node-positive prostate cancer and survival/progression outcome data were presented by intention-to-treat; Selective reporting: One or more outcomes of
interest are reported incompletely so that they cannot be entered in a meta-analysis; Note: Staging was retrospectively regraded to ensure comparable groups.
3 RTOG-85-31: Random sequence generation: Random number generator; Allocation concealment: Central allocation; Blinding of participants/personnel: No; Blinding of outcome assessment: Unclear; Incomplete
outcome data: We found no evidence for missing outcome data for patients with node-positive prostate cancer and survival/progression outcome data were presented by intention-to-treat; Selective reporting: The
study protocol is not available but we suggest that the published reports include all expected outcomes.
4 EPC program: Random sequence generation: Random number generator, Allocation concealment: Central allocation; Blinding of participants/personnel: Double-blinded (placebo-controlled); Blinding of outcome
assessment: Unclear; Incomplete outcome data: We found no evidence for missing outcome data for patients with node-positive prostate cancer and survival/progression outcome data were presented by intention-
to-treat; Selective reporting: The study protocol is not available but we suggest that the published reports include all expected outcomes.
5 Heterogeneity may arise from differences in interventions (radical prostatectomy or radiotherapy) or populations (medical or surgical castration) or different lymph node assessments (lymphangiogram, computed
tomography, lymphadenectomy).
6 EST-3886: Initially planned for 220 lymph node-positive patients but stopped after inclusion of 100 of which only 98 were randomized.
7 Granfors et al.: Initially planned for 400 patients but stopped after inclusion of 91 of which only 39 patients (43%) presented with lymph node-positive disease.
8 RTOG-85-31: Randomization of 977 patients but only 173 (18%) presented with lymph node-positive disease.

















Figure 2 Overall survival. EST-3886, median follow-up 11.9 years; RTOG-85-31, median follow-up 6.5 years; Granfors 2006, follow-up 14–19 years;
AST, androgen suppression therapy. (This figure should be published in the manuscript).
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the studies included.
Adverse events
Two studies (RTOG-85-31, EST-3886) involving 271 pa-
tients with node-positive prostate cancer reported data
on discontinuation due to adverse events. They showed
no significant differences between early and deferred
AST (RR 8.44, 95% CI 0.47-150.35 (5/145 vs. 0/126), not
shown). The authors did not report which outcomes led
to withdrawal. The results were imprecise because the
events described were rare. In addition, the studies were
not placebo-controlled, and the results might therefore
have been biased. Only one study with 98 patients (EST-
3886) reported data on adverse events. This study dem-
onstrated an increased occurrence of adverse events
such as hematological (9/46 vs. 2/50, p = 0.02) and
gastrointestinal adverse events (12/46 vs. 3/50; p < 0.01),
non-specific genitourinary effects (22/46 vs. 6/50; p <
0.01), hot flashes (27/46 vs. 0/50; p < 0.001), gyne-
comastia (10/46 vs. 1/50; p < 0.01), and weight gain
( 8/46 vs. 1/50; p = 0.05) with early AST compared with
deferred AST. The authors did not provide specific defi-
nitions of hematological, gastrointestinal, or non-specific
genitourinary adverse events. The authors reported,
however, that most of these events appeared with gradeFigure 3 Cancer-specific survival. EST-3886, median follow-up 11.9 years
online only).1–2 severity and that AST was well tolerated [13]. No
other adverse events occurred with a significantly differ-
ent frequency between early and deferred AST. The data
for adverse events in RTOG-85-31, the EPC program,
and the study published by Granfors et al. could not be
included because the authors did not report this out-
come consistently for the subgroup of patients present-
ing with node-positive disease after local therapy. The
authors of the RTOG-85-31 study reported only an in-
creased occurrence of hot flashes and more fluid reten-
tion among patients treated with early AST as compared
to deferred AST [9,10]. No study assessed the adverse
events associated with skeletal changes.
Discussion
The available evidence from RCTs might support the
use of early instead of deferred AST for patients with
node-positive prostate cancer following local therapy for
overall survival, cancer-specific survival, and clinical pro-
gression. However, this therapy is probably associated
with an increased frequency of adverse events. The qual-
ity of evidence provided by RCTs is hampered by the
risk of bias.
We included data from studies assessing early versus
deferred AST. The type of AST was, however, varied
among the studies included. This could lead to bias; AST, androgen suppression therapy. (This figure should be published
Figure 4 Clinical progression at 3 years. AST, androgen suppression therapy. (This figure should be published in the manuscript).
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ent AST therapies is still ongoing. LHRH agonists were
found to be as effective as surgical castration with orchi-
ectomy [18]. Orchiectomy is currently performed less
frequently due to its irreversibility and potential negative
psychological effects but is an effective therapy with
which to achieve castration [18]. Current guidelines rec-
ommend that selection between these two therapyFigure 5 Clinical progression at 9 years. AST, androgen suppression theoptions should be made after a discussion that includes
both the patients and the physicians [18]. Non-steroidal
antiandrogens (high-dose bicalutamide) might be an al-
ternative to castration for patients with locally advanced,
non-metastatic disease (M0). The benefit compared with
castration has not been determined [18]. However, we
included the data related to bicalutamide therapy (EPC
program) only for the evaluation of clinical progressionrapy. (This figure should be published in the manuscript).
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after exclusion of data to bicalutamide from meta-analysis.
The risk of potential bias therefore remains low. Unfortu-
nately, our data allowed no identification of outcome dif-
ferences between the different AST therapy options.
We included studies assessing AST for patients that
were treated with either radical prostatectomy or radio-
therapy. Therefore, there might be clinical heterogeneities
considering the type of local therapy that the patient re-
ceived. However, we performed subgroup analyses to ad-
dress potential outcome differences. Both local therapies
(radical prostatectomy or radiotherapy) are often used for
the treatment of localized prostate cancer. However, it
must be considered that the techniques of radiotherapy
and radical prostatectomy have advanced considerably
since these studies were conducted. We are not able to es-
timate how this development can alter the outcome of pa-
tients that are currently treated. This omission should be
addressed when interpreting our data.
We included data from patients with lymph node-
positive disease as assessed by lymphadenectomy or im-
aging. In two studies (RTOG-85-31, EPC program),
imaging was used to define nodal involvement associated
with malignancy. Bias might occur because staging
performed by any method other than lymphadenectomy
might be sub-optimal. Pathological staging is much more
accurate than clinical staging with computer tomog-
raphy. The authors of the study conducted by the Early
Prostate Cancer Program (EPC program) suggested that
most patients with node-positive disease were diagnosed
with radical prostatectomy and therefore had histologi-
cally confirmed nodal status [16]. However, we were un-
able to consider data on the extent of lymph-node
involvement for all included studies. This factor is, how-
ever, known to significantly impact prognosis [19,20].
We included a total of 3 studies for the evaluation of
overall survival, and all reported favorable overall survival
for early AST. We were unable to identify subgroup ana-
lyses concerning node-positive patients from any of the
excluded randomized controlled trials. However, non-
randomized studies provide further evidence for those on
node-positive prostate cancer reporting controversial re-
sults. In contrast to our results, only two observational
studies demonstrated a statistically significant benefit of
early AST [21,22]. Although Myers et al. reported small dif-
ferences between early and deferred AST [23], results from
other observational studies did not favor either of the two
adjuvant therapy options [24-28]. No observational study
showed a significant difference for either early or deferred
AST for cancer-specific survival for patients with node-
positive prostate cancer after local therapy [26-31].
Our results suggest that early AST in patients with
node-positive prostate cancer after local therapy delays
the progression of clinical disease. This conclusion issupported by several observational studies demonstrat-
ing an advantage for early AST as compared to deferred
therapy in patients with node-positive prostate cancer
[24,27,31-33]. There is also evidence from RTOG-85-31
that early AST has a beneficial effect on the incidence of
metastatic disease (time from randomization to clinical
or radiological evidence of disease beyond the pelvis) as
compared to deferred treatment (p = 0.026) [9].
The information available on adverse events is limited,
as they were not consistently reported in all studies.
However, our data suggest that early AST results in an
increased frequency of adverse events; this conclusion is
supported by other reports [34-37]. This should be bal-
anced against a potential improved local control [38]
and a reduced occurrence of complications due to tumor
progression (i.e. cord compression, ureteric obstruction,
and extra-skeletal metastases) [35].
Studies included in the present review compared the ad-
ministration of AST either at the time of local therapy or
symptoms of clinical progression, but PSA was not rou-
tinely used as a marker for disease progression in any of
the studies included. However, PSA testing currently plays
an important role in the detection of prostate cancer and
biochemical disease progression. In modern patient treat-
ment, PSA testing is used to assess the risk for
extraprostatic dissemination or lymph-node involvement,
for example, by using nomograms [39]. This has substan-
tially decreased the proportion of men who are upstaged
with surgery. Current patient cohorts might therefore be
different than those enrolled previously. It might be advis-
able that it is an obligation to follow high-risk patients
using PSA measurement in a regular manner [22,29,40].
The application of our results is hampered by the fact
that the available studies are rather outdated and in-
cluded patients who might no longer represent the con-
temporary population. The risk of bias is also notable.
However, the present study provides the best evidence
on this clinically relevant topic, reporting improved sur-
vival, delayed disease progression, but also more adverse
events among patients with node-positive prostate can-
cer after local therapy treated with early AST as com-
pared to deferred AST. AST is challenging to clinicians
for two reasons: for one, patients with advanced prostate
cancer demand the highest possible quality of life and
are intrigued by the thought of therapy-free intervals
suggesting successful overall management. Second, the
communication of hypotheses regarding the preservation
of androgen dependence in earlier years left many urolo-
gists uncertain about the best use of AST and how to
counsel patients. Thus, the present data offer the best
currently available evidence-based guidance for clini-
cians. Nevertheless, new studies using modern diagnos-
tic evaluation, biochemical testing, and standardized
follow-up schedules are warranted.
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Only four studies could be included in this review. Avail-
able data from small RCTs with an inherent risk of bias
and low quality suggest an improvement of survival, de-
layed disease progression, but also more adverse events
among patients with node-positive prostate cancer after
local therapy treated with early AST as compared to de-
ferred AST. Large RCTs with a low risk of bias should
be conducted to confirm these findings and to evaluate
PSA as a trigger for the initiation of AST.
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